USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ADVANCED GENOMIC TECHNOLOGY, LLC
Address:
Room 118, 580 South Preston Street
LOUISVILLE, KY 40202-1756
Phone:
N/A
URL:
N/A
EIN:
126292862
DUNS:
805479370
Number of Employees:
N/A
Woman-Owned?:
Yes
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $306,666.00 2
SBIR Phase II $1,645,368.00 1

Award List:

Generating Blood-based Diagnosis for Alzheimer Disease

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$107,000.00
Agency:
HHS
Principal Investigator:
Eugenia E. Wang
Abstract:
DESCRIPTION (provided by applicant): The present lack of blood-based diagnosis requires AD patients to be subjected to either invasive spinal fluid (CSF) tapping, expensive MRI or PET imaging, or arduous psychological testing, all unsuitable and costly for our elderly. Strategically, we shall… More

Generating Blood-based Diagnosis for Alzheimer Disease

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$1,645,368.00
Agency:
HHS
Principal Investigator:
Eugenia Wang – 502-852-8331
Abstract:
DESCRIPTION (provided by applicant): The present lack of blood-based diagnosis requires AD patients to be subjected to either invasive spinal fluid (CSF) tapping, expensive MRI or PET imaging, or arduous psychological testing, all unsuitable and costly forour elderly. Strategically, we shall address… More

System for PCS Agencies to Monitor, Investigate and Respond to Elder Safety Risks

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$199,666.00
Agency:
HHS
Principal Investigator:
Eugenia Wang – 502-852-8331
Abstract:
DESCRIPTION (provided by applicant): This project aims to generate blood tests for: 1. mild cognitive impairment (MCI), and 2. conversion risk from MCI to full-blown Alzheimer's disease (AD). We have reported that systemic footprints, increases in key micro- RNA (miR) levels, are identifiable… More